 Dipeptidyl-Peptidase IV Inhibitors
"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
| Descriptor ID |
D054873
|
| MeSH Number(s) |
D27.505.519.389.745.335 D27.505.696.422.500
|
| Concept/Terms |
Dipeptidyl-Peptidase IV Inhibitors- Dipeptidyl-Peptidase IV Inhibitors
- Dipeptidyl Peptidase IV Inhibitors
- Inhibitors, Dipeptidyl-Peptidase IV
- Gliptins
- Dipeptidyl-Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".
This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in this website by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 5 | 1 | 6 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 1 | 2 | | 2017 | 3 | 0 | 3 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles.
-
Hutch CR, Roelofs K, Haller A, Sorrell J, Leix K, D'Alessio DD, Augustin R, Seeley RJ, Klein T, Sandoval DA. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice. Diabetologia. 2019 10; 62(10):1928-1937.
-
Scalzo RL, Rafferty D, Schauer I, Huebschmann AG, Cree-Green M, Reusch JEB, Regensteiner JG. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. J Diabetes Complications. 2019 08; 33(8):561-566.
-
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, Cardona S, Peng L, Pasquel FJ, Umpierrez GE. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Diabetes Obes Metab. 2019 04; 21(4):837-843.
-
Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019 01 01; 123(1):145-152.
-
Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DA. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017 07; 19(7):962-969.
-
Rascati KL, Worley K, Meah Y, Everhart D. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors. J Manag Care Spec Pharm. 2017 Mar; 23(3):299-306.
-
Wyncott D, Lyon C, Mounsey A. PURLs: Need an add-on to metformin? Consider this. J Fam Pract. 2017 01; 66(1):42-44.
-
Pugazhenthi S, Qin L, Bouchard R. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in ß-cells. Eur J Pharmacol. 2015 May 15; 755:42-9.
-
Keller AC, Knaub LA, Miller MW, Birdsey N, Klemm DJ, Reusch JE. Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat. J Cardiovasc Pharmacol. 2015 Feb; 65(2):137-47.
-
Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. Vaccine. 2014 May 30; 32(26):3223-31.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|